For the first time, in known history, EU policy recommendations were made featuring psychedelic-assisted psychotherapy.

”New models of innovative/unusual treatments when they target unmet needs or vulnerable situations, for instance, psychedelic assisted therapies for brain disorders, which constitute a paradigm shift in the pharmacological space because these therapies will need to be registered as both a medicinal product and therapy.”

PAREA provided recommendations on future areas for excellent, innovative and translational brain research in Europe. Shared European Brain Research Agenda covers all brain research fields and brain disorders, including both psychiatric and neurological disorders and will serve as a framework to guide future brain research investments in Europe.

PAREA calls on the EU to embark on more research activity and to stimulate innovation with regard to the use of psychedelics for medicinal purposes.

The European Commission is working on a new ‘Healthier Together’ – EU Non-communicable diseases initiative to support EU countries in reducing the burden of NCDs, focusing on 5 key areas, including mental and neurological disorders. PAREA contributed to this initiative by making a detailed submission as part of the stakeholder consultations

A part of the bi-monthly investor series, this virtual Microdose Conference explores the new technologies driving the industry, the scope of psychedelic investments and the prospects. It offers a forum to connect businesses to the top capitalists and investors of the psychedelic spectrum. These online sessions offer tremendous networking scope where businesses build strong ties and associations.